Research programme: therapeutics for MECP2-associated disorders - Horizon Pharma

Drug Profile

Research programme: therapeutics for MECP2-associated disorders - Horizon Pharma

Alternative Names: Cysteamine and related compounds - Horizon Pharma/Technology Transfer Accelerator of South Eastern France (SATT Sud Est); Mercaptamine and related compounds for Rett syndrome and MECP2-associated disorders - Horizon Pharma

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aix-Marseille University; Curie Institute; INSERM
  • Class Mercaptoethylamines; Small molecules
  • Mechanism of Action Brain-derived neurotrophic factor expression stimulants; Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Rett syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rett syndrome in France
  • 07 May 2013 Preclinical trials in Rett syndrome in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top